Stocks and Investing
Stocks and Investing
Mon, February 12, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Chris Shibutani Upgraded (UTHR) to Hold and Increased Target to $215 on, Feb 12th, 2024
Chris Shibutani of Goldman Sachs, Upgraded "United Therapeutics Corporation" (UTHR) to Hold and Increased Target from $213 to $215 on, Feb 12th, 2024.
Chris has made no other calls on UTHR in the last 4 months.
There are 4 other peers that have a rating on UTHR. Out of the 4 peers that are also analyzing UTHR, 0 agree with Chris's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Chris
- Roanna Ruiz of "Leerink Partners" Initiated at Buy and Held Target at $330 on, Monday, February 5th, 2024
- Terence Flynn of "Morgan Stanley" Maintained at Buy with Decreased Target to $314 on, Thursday, November 2nd, 2023
- Jessica Fung of "JP Morgan" Maintained at Buy with Increased Target to $294 on, Thursday, November 2nd, 2023
- Liana Moussatos of "Wedbush" Maintained at Buy with Increased Target to $308 on, Thursday, November 2nd, 2023
Contributing Sources